Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

High fatty acid binding protein 4 predicts pre-eclampsia

10 Sep 2018
The study reaffirms that low-dose aspirin can be considered as a prophylactic of preterm delivery for women at high risk of preeclampsia

High fatty acid binding protein 4 (FABP4) concentrations during the first prenatal visit is an independent predictor of pre-eclampsia, a recent study has shown.

Using enzyme-linked immunosorbent assays, researchers measured serum FABP4 levels in 1,486 women in early pregnancy (median age 28.0 years). Sixty-one of the participants developed pre-eclampsia, yielding an incidence rate of 4.1 percent.

Median FABP4 concentrations measured during the first prenatal visit were significantly higher in participants who eventually developed pre-eclampsia than in those who did not (24.8 vs 15.6 ng/mL; p<0.001). Moreover, the incidence rate increased along with quartiles of FABP4 levels (Q1: 1.3 percent; Q2: 2.7 percent; Q3: 4.8 percent; Q4: 7.5 percent).

Multivariate logistic regression models provided further confirmation of these findings. For each unit increase in FABP4, there was a 4-percent corresponding increase in the risk of pre-eclampsia (adjusted odds ratio [OR], 1.04; 94 percent CI, 1.02–1.07; p=0.015) and a 9-percent increase in the likelihood of severe pre-eclampsia (adjusted OR, 1.09; 1.04–1.16; p=0.004).

Comparing FABP4 quartiles yielded a similar trend. Relative to quartile 1, those in quartiles 3 (adjusted OR, 2.21; 1.09–4.18) and 4 (adjusted OR, 3.05; 1.43–7.75) were at significantly higher risks of developing pre-eclampsia. No such effect was observed for quartile 2 (adjusted OR, 1.18; 0.47–4.13).

Notably, even when compared against quartiles 1–3 together, the fourth quartile of FABP4 was significantly prognostic of pre-eclampsia (OR, 2.07; 1.06–3.98; p=0.009).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.